[Table_Chart] 行业指数与沪深 300 走势比较 0% 11% 21% 32% 7/24 10/24 1/25 4/25 主要观点： [Table_Summary] 华安证券化工团队发表的《合成生物学周报》是一份面向一级市场、 二级市场，汇总国内外合成生物学相关领域企业信息的行业周报。 目前生命科学基础前沿研究持续活跃，生物技术革命浪潮席卷全球并 加速融入经济社会发展，为人类应对生命健康、气候变化、资源能源 安全、粮食安全等重大挑战提供了崭新的解决方案。国家发改委印发 《"十四五"生物经济发展规划》,生物经济万亿赛道呼之欲出。 D [Table_IndNameRptType] 基础化工 行业周报 合成生物学周报：江西出台精细化工新政，AI 与合成 生物融合研发平台在安徽芜湖落地建设 [Table_IndRank] 行业评级：增持 报告日期： 2025-07-13 合成生物学指数是华安证券研究所根据上市公司公告等汇总整理由 58 家业务涉及合成生物学及其相关技术应用的上市公司构成并以2020年 10 月 6 日为基准 1000 点，指数涵盖化工、医药、工业、食品、生物 医药等多领域公司。本周（202 ...

公司公告汇总 卓越新能关于在泰国投资建设生物能源生产线项目的公告：龙岩卓越新能源股份有限公司拟投资7亿 元，在泰国春武里府建设生物能源生产线项目，包括年产30万吨生物柴油生产装置、年产10万吨HVO （烃基生物柴油）/SAF（生物航空燃料）联合生产装置及相应配套装置。项目将分期实施，一期先行 完成年产30万吨生物柴油生产线及配套装置建设，由卓越新能源（泰国）有限责任公司负责具体落地实 施。项目总投资额7亿人民币，建设周期预计为12个月。项目存在跨境投资和市场风险，公司已取得国 内境外投资项目备案手续，获得泰国投资委员会BOI批准证书，完成土地租赁合同签署，并开始土地勘 探，有序推进项目建设。 卓越新能关于2024年度以简易程序向特定对象发行股票预案修订说明的公告：龙岩卓越新能源股份有限 公司关于2024年度以简易程序向特定对象发行股票预案修订说明的公告。公司于2024年12月5日召开第 五届董事会第七次会议审议通过了发行股票预案等相关议案，2025年7月8日召开第五届董事会第十次会 议通过竞价结果及股份认购协议等议案。本次发行拟认购金额为30000万元，符合简易程序向特定对象 发行融资总额规定。根据股东大会授 ...

Core Insights - UniFirst Corporation has been recognized for 22 consecutive years on Selling Power's list of the "60 Best Companies to Sell For in 2025," highlighting its strong sales culture and commitment to customer service [1][4]. Company Overview - UniFirst is a North American leader in providing customized business uniform programs, facility service products, and first aid and safety services [1][6]. - The company serves over two million uniform wearers across North America, including more than half of the Fortune 500 companies [4]. Sales Culture - The company's sales culture is built on its Founding Core Values: Customer Focus, Commitment to Quality, and Respect for Others [3]. - UniFirst empowers its sales teams to understand customers' businesses deeply, enabling them to develop innovative strategies that address unique challenges [3][4]. Recognition and Evaluation - Selling Power evaluates companies based on their supportive and collaborative sales culture, with a focus on professionalism, trust, and empowerment [4]. - The recognition reflects UniFirst's long-term success in sales and customer engagement [4]. Recruitment and Growth - UniFirst is actively recruiting talented individuals to join its award-winning sales team, indicating ongoing growth and expansion [5].

中国石化联党委常委、外资委主任委员兼秘书长庞广廉介绍了中国石化联的职能职责及石化产业近期、 中期、远期补链延链的发展方向，并同北海市政府在战略规划、招商引资、资源嫁接与落地等方面进行 未来合作探讨。 李莉和北海市委常委、统战部部长、副市长龙起云分别介绍了北海市石化产业发展现状及存在的问题。 石油和化学工业规划院副院长郑宝山在分析全国石化产业集约化、绿色化转型趋势的基础上，结合北海 市深水良港、毗邻东盟、清洁能源富集等核心优势，提出综合发展建议。他强调，北海市石化产业发展 需立足国家能源安全战略高度，主动承接国家战略布局，并尝试中外合资模式发展产业。在产业转型升 级方面，郑宝山认为应推动现有炼油产能向高端化学品转型，布局风电制氢耦合绿色甲醇、可持续航空 燃料(SAF)等低碳项目。 中化新网讯 7月8日，中国石油和化学工业联合会(下称中国石化联)同广西北海市政府进行交流座谈，双 方就北海石油化工产业总体发展形势、"十五五"时期发展规划等议题进行深入交流。北海市委副书记、 市长李莉，中国石化联党委书记、会长李云鹏参加座谈。 李云鹏对李莉一行的到访表示欢迎。他表示，中国石化联始终聚焦服务国家、服务社会、服务群众、服 ...

Company Overview - Gevo, Inc. is a diversified energy company focused on producing renewable products, including synthetic aviation fuel, motor fuels, and chemicals, aimed at enhancing energy security and supporting rural economic growth [4] - The company operates one of the largest dairy-based renewable natural gas (RNG) facilities in the U.S. and has an ethanol plant with a carbon capture and sequestration facility [4] Recent Financial Developments - Barclays Capital Inc. has purchased $40 million of newly issued non-recourse tax-exempt private activity bonds for Gevo's subsidiary, Gevo NW Iowa RNG, LLC, which will refinance $40 million of previously issued bonds [1] - This refinancing allows Gevo to release $40 million of restricted cash and improve its balance sheet liquidity by approximately $30 million after transaction costs [1][2] Renewable Natural Gas Operations - Gevo RNG generates RNG by collecting manure from dairy farms and using anaerobic digesters to produce biogas, which is refined for use as a sustainable transportation fuel [3] - The company has received CARB certification for a carbon intensity score of negative 339 gCO2e/MJ, which will be used for California's Low Carbon Fuel Standard credits, potentially yielding over 175,000 metric tons of greenhouse gas emissions reductions annually [3] Future Plans - Gevo plans to release additional restricted cash later in the year by refinancing the remaining balance of the previous bonds through another series of 2025 Bonds [2] - The company is exploring opportunities for scaling and margin expansion in its RNG business and aims to leverage synergies with its other business lines [3]

BOCA RATON, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- ADT Inc. (NYSE: ADT) will release its second quarter 2025 financial results before the market opens on Thursday, July 24, 2025. Following the release, management will host a conference call at 10 a.m. ET to discuss the financial results and lead a question-and-answer session. Participants may listen to a live webcast through the investor relations website at investor.adt.com. A replay of the webcast will be available on the website within 24 hours of the l ...

Core Points - The deadline for potential buyers to submit preliminary bids for Global Bioenergies has been extended to 18 July 2025, allowing more time for interested parties to conduct their studies [2] - Two offers and three letters of intent have been received, indicating interest in the company's assets [2] - A review hearing for final offers is expected to take place in September or October [3] Company Situation - Global Bioenergies is undergoing a pre-pack sale process aimed at maintaining business activities and jobs, but shareholders will not receive compensation, leading to a total loss of their investments [5] - The company has significant debts amounting to €13 million, which has hindered its ability to finance future operations as a listed entity [5] - Despite a promising partnership project with an undisclosed major industrialist, the company was unable to bring its solution to the Sustainable Aviation Fuel (SAF) market [5] Technology and Market Position - Global Bioenergies has developed a unique process for producing SAF and e-SAF from renewable resources, contributing to the decarbonization of air transport [6] - The company's technology is one of the few certified by ASTM, and its products meet high standards in the cosmetics industry, with L'Oréal being the largest shareholder at 13.5% [6]

Core Viewpoint - Ascentage Pharma's novel Bcl-2 selective inhibitor, lisaftoclax (APG-2575), has received conditional approval from China's National Medical Products Administration (NMPA) for treating adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously undergone at least one systemic therapy, marking it as the first Bcl-2 inhibitor approved for this indication in China and the second globally [1][3][7] Company Overview - Ascentage Pharma is a global biopharmaceutical company focused on addressing unmet medical needs in cancer treatment, with a rich pipeline of innovative drug candidates, including inhibitors targeting key proteins in the apoptotic pathway [10][11] - The approval of lisaftoclax represents a significant milestone in the company's development efforts, following its first commercialized drug, olverembatinib [2][10] Product Details - Lisaftoclax is an orally administered small-molecule Bcl-2 selective inhibitor designed to restore normal apoptosis in cancer cells by blocking the antiapoptotic protein Bcl-2 [2][5] - The drug has demonstrated broad therapeutic potential in various hematologic malignancies and solid tumors, particularly in CLL/SLL, both as a monotherapy and in combination therapies [2][3] Clinical Study Insights - The approval was based on a pivotal Phase II study (APG2575CC201) that evaluated the efficacy and safety of lisaftoclax in patients with relapsed or refractory CLL/SLL, achieving a compelling overall response rate (ORR) that met the prespecified endpoint [3][4] - Lisaftoclax exhibited a favorable safety profile, with no occurrences of tumor-lysis syndrome (TLS) and manageable hematologic and non-hematologic toxicities [3][4] Market Context - CLL/SLL is a common hematologic malignancy, particularly affecting older populations, with over 100,000 new diagnoses globally each year [4] - In China, the incidence of CLL/SLL is rising, necessitating safer and more effective treatment options beyond the current primary therapies, such as BTK inhibitors, which have limitations including high relapse rates and associated toxicities [4][5][6] Future Development Plans - Ascentage Pharma is conducting four global registrational Phase III trials for lisaftoclax, including studies in combination with BTK inhibitors and in various hematologic malignancies [7][13] - The company aims to accelerate the global development of lisaftoclax to address unmet clinical needs and expand its therapeutic applications [7][13]

Company Overview - LiveRamp Holdings is a San Francisco-based data-connectivity platform that is experiencing rising earnings expectations even in a volatile market [2] - The company has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a significant upward trend in analysts' earnings estimates [2] Earnings and Revenue Growth - The current year Zacks Consensus Estimate for LiveRamp has increased from $2.86 to $2.88, forecasting a 26% earnings growth for next year following a 34% growth this year [3] - Revenue growth is also strong, projected at 7.6% for this year and 11.3% for the next year [3] Industry Position - LiveRamp operates within the Technology Services industry, which ranks in the Top 21% of the Zacks Industry Rank [4] - The company's products, such as IdentityLink, Safe Haven, Privacy Manager, and Authenticated Traffic Solutions (ATS), are essential for marketers navigating privacy regulations and the decline of third-party cookies [4] Stock Performance - LiveRamp's stock has been on the rise since Q2 2024, correlating with increased earnings estimates [5] - Although the last quarter's earnings report met revenue expectations, it missed earnings by 3.23%, marking the first earnings miss since Q1 2023 [5]

NASHVILLE, TN, July 10, 2025 (GLOBE NEWSWIRE) -- American Rebel Holdings, Inc. (NASDAQ: AREB) (“American Rebel” or the “Company”), the creator of American Rebel Beer (americanrebelbeer.com) and a leading designer and marketer of branded safes, personal security products, and patriotic apparel, today announced plans to expand its brand platform through the formation of a new wholly owned subsidiary, American Rebel Productions, LLC. As part of this strategic initiative, the Company has entered into a professi ...